FPF 1070

Drug Profile

FPF 1070

Alternative Names: Cerebrolysin

Latest Information Update: 08 Oct 2015

Price : $50

At a glance

  • Originator Ebewe Neuro Pharma
  • Developer EVER Neuro Pharma
  • Class Nootropics; Peptides; Tissue extracts
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Stroke
  • Discontinued Brain injuries

Most Recent Events

  • 18 Aug 2009 Discontinued - Phase-II for Brain injuries in Austria (IV)
  • 18 Aug 2009 Discontinued - Phase-II for Brain injuries in Spain (IV)
  • 22 Mar 2005 Data presented at the 7th International Conference on Alzheimer's Disease and Parkinson's Disease (ADPD-2005) have been added to the Alzheimer's disease therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top